Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 389,900 shares, a growth of 1,230.7% from the February 13th total of 29,300 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily trading volume, of 336,300 shares, the short-interest ratio is currently 1.2 days.

Chemomab Therapeutics Trading Up 4.0 %

NASDAQ CMMB traded up $0.06 during trading on Wednesday, hitting $1.42. 23,731 shares of the company traded hands, compared to its average volume of 424,338. The company has a market capitalization of $20.32 million, a P/E ratio of -1.42 and a beta of 0.54. The business has a fifty day simple moving average of $1.91 and a 200 day simple moving average of $1.75. Chemomab Therapeutics has a 12 month low of $0.58 and a 12 month high of $2.55.

Institutional Trading of Chemomab Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. bought a new position in Chemomab Therapeutics in the 3rd quarter worth $1,907,000. Virtu Financial LLC acquired a new position in shares of Chemomab Therapeutics during the 4th quarter worth about $26,000. Finally, XTX Topco Ltd boosted its stake in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares during the period. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on CMMB. Oppenheimer reiterated an “outperform” rating and set a $11.00 price target (down from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th. Maxim Group lifted their target price on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).